Media headlines about Aduro BioTech (NASDAQ:ADRO) have trended somewhat positive on Monday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aduro BioTech earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.1900486601761 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of research firms have recently commented on ADRO. HC Wainwright set a $18.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Oppenheimer reduced their price objective on shares of Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, December 13th. BidaskClub downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 3rd. William Blair restated an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, Canaccord Genuity set a $30.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Aduro BioTech has an average rating of “Buy” and a consensus price target of $17.71.
Shares of Aduro BioTech (NASDAQ:ADRO) traded up $0.40 during trading hours on Monday, reaching $7.30. 637,500 shares of the company traded hands, compared to its average volume of 418,731. Aduro BioTech has a twelve month low of $6.01 and a twelve month high of $14.05. The firm has a market cap of $575.91 and a P/E ratio of -5.37.
Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. During the same quarter last year, the business posted ($0.54) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. research analysts expect that Aduro BioTech will post -1.28 EPS for the current year.
In other Aduro BioTech news, COO Gregory W. Schafer sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $7.97, for a total transaction of $159,400.00. Following the completion of the sale, the chief operating officer now directly owns 155,677 shares in the company, valued at $1,240,745.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stephen T. Isaacs sold 20,200 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $7.98, for a total transaction of $161,196.00. Following the sale, the insider now owns 190,321 shares of the company’s stock, valued at $1,518,761.58. The disclosure for this sale can be found here. Insiders sold a total of 267,714 shares of company stock valued at $2,251,452 over the last quarter. 6.60% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Aduro BioTech (ADRO) Getting Somewhat Favorable Press Coverage, Study Shows” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/22/aduro-biotech-adro-getting-somewhat-favorable-press-coverage-study-shows.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.